Canaccord analyst Sumant Kulkarni raised the firm’s price target on Neurocrine (NBIX) to $154 from $150 and keeps a Buy rating on the shares. The firm continues to like the stock as execution on Ingrezza remains robust, the Cardinal Health (CAH) opportunity is underappreciated, and current valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
- Neurocrine sees FY24 INGREZZA net product sales $2.1B-$2.2B
- Neurocrine reports Q4 adjusted EPS $1.54, consensus $1.14
- NBIX Earnings this Week: How Will it Perform?
- Neurocrine price target raised to $150 from $145 at Barclays
